FUJIKURA
Fujikura Ltd. (TOKYO:5803) (President & CEO: Masahiko Ito) today announced the introduction of industry’s most advanced and highly integrated Phased Array Antenna Module (PAAM) for 5G mmWave operating in 3GPP bands n257 (28 GHz), n258 (26 GHz) and n261 (27 GHz). The Fujikura PAAM is the industry’s highest performance PAAM targeting indoor and outdoor applications such as 5G mmWave Fixed Wireless Access (FWA), 5G mmWave Mobile Wireless Access (MWA), 5G mmWave wireless backhaul, and other emerging applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201023005099/en/
Key Differentiating Features of the Fujikura PAAM
The Fujikura PAAM is a high performance phased array antenna module with a novel integrated antenna, and supports concurrent dual polarized beams in both transmission and reception (Fig.1). The PAAM integrates best-in-class mmWave-ICs developed in-house using an industry leading SiGe BiCMOS process. The PAAM features extremely low noise figure (NF) characteristics and enables a large link margin for expanded coverage. Tunable true-time-delay-type phase shifters support precise and independent phase and amplitude control over a wide frequency range. The unique phase shifter not only enables simple beam-steering control which allows accurate beam steering with fine resolution, but also allows calibration-free operation making PAAM installation much easier. The phase shifter also maintains the transmitted or received signals undistorted by providing invariant group delay and unchanged beam direction in a wide frequency range. In addition, Fujikura PAAM provides superior digital reconfigurability allowing (1) flexible choices in the trade-off space between NF and linearity --- this enables a wide range of coverage applications simply through digital reconfiguration of the PAAM, and (2) on-chip support for 1000s of beam configurations. These are exactly the features highly desired by 5G wireless equipment manufacturers.
5G mmWave Market Growth
Currently, 5G deployments are accelerating around the world and mmWave bands are expected to play a significant role in enhancing the network capabilities. According to the Global mobile Suppliers Association (GSA), by the end of August, 2020, 397 operators in 129 countries and territories had announced investments in 5G. The deployment of 5G mmWave has started primarily in the US market for FWA and MWA, and we are now in the early stages. Markets are expecting substantial increase in 5G mmWave use cases including both outdoor and indoor deployments around the world. Fujikura will contribute to this market growth and benefit from it by providing 5G mmWave infrastructure customers with best-in-class PAAM products.
“Fujikura is announcing its first 5G mmWave RF-IC products for mobile infrastructure. Fujikura n257/n258/n261 PAAM products leverage field proven 5G mmWave IC1 and antenna in package2 technologies developed at IBM Research and enhanced by a Fujikura-led Joint Development Program3,4 . Leveraging our expertise in antenna design and substrate technologies as well as our long history and expertise in delivering differentiating products to the telecom industry, we are excited to introduce our new PAAM product family,” said Kenji Nishide, Fujikura R&D Managing Executive Officer. “Fujikura’s PAAM sets new benchmarks in terms of performance and low power consumption with the highest level of integration for 5G mmWave RF-ICs, which will contribute to growth and expansion of 5G mmWave networks and services.”
Product Introduction Schedule
Fujikura will provide samples for early access customers by the end of 1Q 2021 with volume production in 2H 2021.
For More Information
Please visit our website (https://mmwavetech.fujikura.jp/#area-28ghz-module
) and contact us.
About Fujikura
Fujikura Ltd. is a Tokyo-based company that has been providing wires and cables—“Tsunagu,” or connecting, technologies— to build social infrastructure since its foundation in 1885. With this expertise cultivated over 130 years, we commit to contribute to building social infrastructure by developing products for optical fibers, broadband wireless transmission, superconducting wires, electric vehicles, and other advanced technologies. Fujikura Group has approximately 57,000 employees in more than 30 countries, and posted sales revenue of US$6,178.7 million in Fiscal 2019. Find out more at www.fujikura.co.jp/eng
.
Reference
[1] https://www.ibm.com/blogs/research/2018/02/isscc-lewis-winner-award/
[2] https://www.ibm.com/blogs/research/2017/06/using-air-cavity-boost-performance-5g-antenna-module/
[3] https://www.fujikura.co.jp/eng/newsrelease/products/2058964_11777.html
[4] https://mmwavetech.fujikura.jp/
View source version on businesswire.com: https://www.businesswire.com/news/home/20201023005099/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AppLogic Networks Announces Strategic Rollout of Industry-First, Comprehensive 400GE Networking Enablement Across Virtual and Appliance-Based Network Domains to Meet Explosive Data Growth8.7.2025 15:00:00 CEST | Press release
Innovative solution represents cost-efficient, streamlined offering with multiple deployment options, catering to both physical networking appliances and virtual infrastructure, while delivering superior performanceEnables Tier 1 and Tier 2 fixed and mobile network operators to accelerate deployment, simplify maintenance, and scale without the need for massive infrastructure investment AppLogic Networks, a leader in application classification and high-performance software-based networking solutions, today announced a significant expansion of its portfolio to support 400 Gigabit Ethernet (400GE) across both traditional appliance-based and virtual infrastructure domains. This move comes as telecom and service providers worldwide face unprecedented growth in network traffic, fueled by 4K/8K streaming, cloud gaming, AI workloads, and IoT proliferation. As part of this expansion, AppLogic Networks now offers comprehensive 400GE enablement and interoperability in its flagship data plane plat
Boyd Unveils a High-Capacity Coolant Distribution Unit with a 2.3 Megawatt Capacity for AI Liquid Cooling Applications8.7.2025 14:05:00 CEST | Press release
Boyd’s ROL2300 Coolant Distribution Unit Efficiently and Reliably Cools Modern High Power AI Processors in Hyperscaler, Colocation, and Enterprise Data Centers Today, Boyd announces a significant expansion of its liquid cooling product portfolio with a new high-capacity coolant distribution unit (CDU). Boyd’s new ROL2300 is a liquid-to-liquid in row system that enables high performance cooling for modern AI processor applications and is immediately available to purchase in volume. To learn more about the ROL2300, watch the video here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708530818/en/ Boyd's high capacity ROL2300 in row coolant distribution unit (CDU) efficiently and reliably cools modern high power AI processors in hyperscale, colocation, and enterprise data centers with up to a 2.3 megawatt capacity. A single ROL2300 can efficiently cool over 10 NVL72 racks. It is optimized to easily fit in data center server
Breakthrough in Ophthalmology! Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as First Treatment for Dry Eye Disease Associated with MGD8.7.2025 14:00:00 CEST | Press release
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”), a global pharmaceutical company focused on scientific and technological innovation, and Novaliq GmbH (“Novaliq”), a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, announce today that the China National Medical Products Administration (NMPA) has approved Heng Qin® (Perfluorohexyloctane Eye Drops) for the treatment of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD). Heng Qin® is the first and only drug approved to treat DED associated with MGD and will be available to patients in China in the coming months. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708514269/en/ Heng Qin® is the first and only drug approved to treat DED associated with MGD and will be available to patients in China in the coming months. According to the Chinese Expert Consensus on M
Esri Launches New E-Commerce Experience for Demographic Data8.7.2025 14:00:00 CEST | Press release
Organizations Can Purchase Updated, Authoritative Datasets Ranging from Census to Retail Demand To further provide individuals and organizations with the authoritative demographic data they need, Esri, the global leader in geographic information system (GIS) technology, has launched a new e-commerce experience for data in the Esri Store. A one-stop shop for enhanced, reliable information relating to people and geography, Esri’s location data store is designed to make these resources more accessible for users that rely on spatial data. “We are thrilled to launch our new e-commerce experience, making it easier than ever for customers to access the data they need to make better decisions,” said Rob Elkins, Esri director of product management. “Organizations will have access to current-year and five-year estimates for more than 2,000 demographic and socioeconomic characteristics in the US, as well as census and American Community Survey (ACS) information, consumer spending trends, market p
Vanderbilt Selects Parse Biosciences GigaLab to Generate Atlas of Early Neutralizing Antibodies to Measles, Mumps, and Rubella8.7.2025 14:00:00 CEST | Press release
Researchers aim to discover dominant subtypes of plasmablasts initiating from the MMR vaccine in order to develop neutralizing antibody candidate therapies The Vanderbilt University Medical Center and Parse Biosciences today announced a strategic collaboration to generate a single cell atlas focused on understanding the diversity of plasmablasts – early immune cell clonotypes critical in the formation of neutralizing antibodies – for measles, mumps and rubella. This effort aims to build the most comprehensive understanding of the formation of neutralizing antibodies to the vaccine and to identify the dominant and effective antibodies to these infectious agents. Dr. James Crowe, Director of Vanderbilt's Center for Antibody Therapeutics, will lead the development of the large-scale immune cell study. “This collaboration enables us to create the largest single cell atlas of neutralizing plasmablasts ever assembled,” states Crowe. “By sequencing and mapping tens of millions of B cell recep
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom